Biocon shares in focus after board opens up QIP fundraising on 16 June, sets floor price at ₹340.20/share
'The Fund Raising Committee has at its meeting held today, i.e. Monday, June 16, 2025, authorizing the opening of the issue,' said Biocon in the BSE filing.
The pharma company also approved the floor price of the QIP issue to be at ₹ 340.20 per equity share. Biocon disclosed that the company has the ability to discount the offer further to not more than 5 per cent on the floor price of the QIP issue.
'The company may, at its discretion, offer a discount of not more than 5% on the floor price for the issue,' said Biocon in the exchange filing.
The firm will decide the issue price after consultation with the book-running lead managers appointed in relation to the case.
Biocon shares closed 0.52 per cent higher at ₹ 357.30 after Monday's stock market session, compared to ₹ 355.45 at the previous stock market close. The company announced the outcome of its board meeting after the market operating hours on 16 June 2025.
Shares of the pharmaceutical company have given investors more than 637.35 per cent since its listing in the Indian stock market in 2004. However, the shares lost 6.37 per cent in the last five years.
In the last one-year period, the stock has gained 8.71 per cent, and is trading 4.31 per cent higher in the last five stock market sessions.
Biocon shares hit their 52-week high level at ₹ 404.60 on 21 January 2025, and the 52-week low level was at ₹ 290.80 on 3 March 2025, according to data collected from the BSE website. The pharma company's market capitalisation (M-Cap) was at ₹ 42,897.44 crore as of the stock market close on Monday, 16 June 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
26 minutes ago
- Economic Times
Vijay Kedia-owned SME stock jumps 16% in 2 days as unit eyes Nasdaq IPO
Kedia holds a 14.6% stake in the company, one of only three stocks in his portfolio where his holding is above 10%. Synopsis Tac Infosec shares surged following its U.S. subsidiary, CyberScope's, announcement of a planned Nasdaq IPO, a first for an India-listed cybersecurity firm. Veteran investor Vijay Kedia, holding a significant 14.6% stake, has seen his investment appreciate. The stock's performance shows short-term strength but longer-term weakness, with mixed technical indicators. Veteran investor Vijay Kedia's portfolio stock Tac Infosec surged as much as 5% on Wednesday to Rs 985.7 on the BSE, extending a two-day rally to 15.8%, after its U.S.-based subsidiary announced plans to pursue a Nasdaq listing, marking a first-of-its-kind move for an India-listed cybersecurity firm. ADVERTISEMENT Kedia holds a 14.6% stake in the company, one of only three stocks in his portfolio where his holding is above 10%. The other two are Atul Auto and Innovators Facade Systems, in which he owns 20.9% and 10.7% respectively. Tac Infosec, in a press release, said its wholly owned subsidiary, CyberScope Web3 Security Inc., incorporated in the Cayman Islands, has approved filing a confidential Draft Registration Statement with the U.S. Securities and Exchange Commission for a proposed Nasdaq Capital Market IPO. 'This is a truly historic milestone, not only for TAC InfoSec but also for India's wider technology and cybersecurity landscape. By embarking on the path towards a Nasdaq listing, CyberScope is taking a bold step that elevates its vision and innovation to the global arena,' said Trishneet Arora, Founder and CEO of TAC Tac Infosec stock, listed on the NSE in April 2024, has gained 7% over the last month and 57% over the past year. ADVERTISEMENT From a technical perspective, the stock is trading above five of its eight key simple moving averages (5-day to 50-day), suggesting short-term strength, while lagging its 100-day, 150-day, and 200-day SMAs, indicating longer-term weakness. The Relative Strength Index stands at 53.3, while the MACD remains below the centre line. Unlock 500+ Stock Recos on App Kedia, one of India's most closely tracked investors, began investing at 19 and set up Kedia Securities in 1992. His publicly disclosed portfolio, according to Trendlyne, spans 14 companies with a combined market value of over Rs 1,228.1 crore. ADVERTISEMENT Also read | Vijay Kedia exits Tata stock after making multibagger returns in 5 years (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel) NEXT STORY
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Russia invites Indian exports as US tariffs hit trade, defends oil ties
India can sell more of its products to Russia if it faces challenges in the US market, a senior Russian diplomat said on Wednesday, defending New Delhi's continued purchase of Russian crude oil despite mounting American pressure. At a press conference in New Delhi, Russian Deputy Chief of Mission Roman Babushkin called Washington's stance on India's energy trade with Moscow 'unjustified' and 'unilateral". 'If Indian goods are facing difficulties entering the US market, the Russian market is welcoming Indian exports,' he said. 'The sanctions are hitting those who are imposing them. It is a challenging situation for India but we have trust in our ties. We are confident that India-Russia energy cooperation will continue notwithstanding the external pressure.' #WATCH | Delhi | Roman Babushkin, Chargé d'Affaires of the Russian Embassy in India, says, " (EAM) Dr S Jaishankar is in Moscow. He will meet Mr Lavrov tomorrow. They will discuss everything important, including global issues." — ANI (@ANI) August 20, 2025 'India-Russia ties built on complementarity' Babushkin stressed that Moscow remains India's largest crude oil supplier and that the two economies complement each other. 'Let's proceed from the fact that Russia is the biggest supplier to India of crude oil. And India's demands are growing year by year. Certainly, this is a perfect case of mutual accommodation and complementarity of our economies. We are quite certain that our cooperation will continue,' he said. The Russian diplomat's remarks came a day after White House Press Secretary Karoline Leavitt said US President Donald Trump had imposed new tariffs on India to "discourage" Russia from continuing the Ukraine conflict. A 25 per cent duty is set to take effect on August 27, with Washington already warning of sanctions on countries purchasing Russian oil. India and China are the two largest buyers. Jaishankar in Moscow as tensions rise The comments also coincided with External Affairs Minister S Jaishankar's three-day visit to Russia, where he is scheduled to meet Foreign Minister Sergei Lavrov. According to Babushkin, Western nations cannot be trusted to treat India as an equal partner. 'If India refuses Russian oil, it will not lead to equal cooperation with the West in general because it is not in the Western nature, which was clearly demonstrated in recent years. They behave like neocolonial powers that think of their own benefit. This pressure is unjustified and unilateral,' he said. He added, 'If the West criticises you, it means you are doing everything right. We don't expect that to happen (India to stop buying oil from Russia). We know about the challenging circumstances for India. This is the true strategic partnership we are enjoying.' Putin-Modi talks underline partnership Babushkin also highlighted the recent phone call between Prime Minister Narendra Modi and Russian President Vladimir Putin. 'The recent phone call by President Putin to PM Modi ji, explaining and sharing the information about recent developments in Ukraine, means India matters a lot to Russia. We are capable of finding any solution for mutual satisfaction. The deepening of our partnership will help us grow together,' he said. He pointed out that despite years of Western sanctions, bilateral trade had grown significantly. 'We have seen this problem of sanctions for many years now, but our trade is growing. In recent years, our trade has grown by seven times,' he noted. Russia slams US 'double standards' The Russian diplomat criticised Washington for straining ties with New Delhi while calling itself a partner. 'As we all know, the sanctions are a tool of unlawful competition. It's always about double standards. A lack of trust, blackmail and pressure, as well as disrespect of national interests. Friends don't behave like that,' he said. He added that Russia and Brics countries never impose sanctions, calling non-UN and secondary sanctions 'illegal". 'They just weaponise the economy. Despite the tremendous sanction pressure on Russia, you will see the Russian economy is growing steadily,' he said. US tariffs hit Indian exports On August 6, Trump announced an additional 25 per cent duty on Indian goods over New Delhi's continued oil imports from Russia. He later doubled the tariff to 50 per cent, the highest imposed on any country apart from Brazil. Key Indian export sectors such as textiles, leather, and marine products are expected to be badly hit. India condemned the move as 'unfair, unjustified and unreasonable'. Prime Minister Modi has said New Delhi will not bow to economic pressure. Leavitt later clarified that the sanctions aimed to put 'secondary pressure on Russia.' She added, 'The president has put tremendous public pressure to bring this war to a close. He's taken actions, as you've seen, sanctions on India and other actions as well.' (With ANI inputs)
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva
Aurobindo Pharma has emerged as the leading contender to buy Prague-based drugmaker Zentiva from private equity (PE) firm Advent International in a deal estimated at $5-5.5 billion, The Economic Times reported on Wednesday, citing sources. If the deal goes through, it would mark the biggest acquisition by an Indian pharmaceutical company globally. Another firm in the fray includes the United States (US)-based private equity firm GTCR, the report added. 'No binding agreement' yet: Aurobindo However, soon after the report surfaced, Aurobindo issued a clarification stating that "no binding agreement or definitive decision" has been made yet regarding the deal. "The Company regularly explores various strategic opportunities in the ordinary course of its business, including potential acquisitions and partnerships, to enhance long-term shareholder value. However, at present, no binding agreement or definitive decision has been made by the board of directors of the company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon," the company said in a BSE filing. European push The deal could further expand Aurobindo's presence in the European market, where the firm is already performing well. In the first quarter of the financial year 2025-26 (Q1 FY26), it reported an 18 per cent year-on-year (Y-o-Y) revenue growth in European markets, which stood at ₹2,338 crore, driven by a strong performance across all key segments. Similarly, revenue from growth markets formulations increased by 8.8 per cent Y-o-Y to ₹772 crore in the June quarter, compared to ₹709 crore in the same period last year. Overall, Aurobindo Pharma reported a 10.2 per cent Y-o-Y drop in consolidated profit after tax (PAT) for Q1 FY26, which stood at ₹824 crore. The decline was attributed to a drop in sales in its active pharmaceutical ingredients business and the US market. However, the drugmaker recorded a 4 per cent rise in revenue from operations, reaching ₹7,868 crore in the June quarter, up from ₹7,567 crore in Q1 FY25. Shares of Aurobindo Pharma fell almost 4 per cent to ₹1,047 apiece on the BSE at 2:14 pm following the report.
